Report
Oliver Metzger

Fresenius Medical Care : Q3 review – Beat on bottom line

>Q3 review – strong bottom line performance ahead of expectations - Fresenius Medical Care's Q3 2024 revenues of € 4,760m (-3.6% y-o-y, 0%/-1% vs ODDO BHF/consensus) were supported by organic growth of 1.9% at group level compared with our forecast of 2.4%. Divestments created a headwind of 430bp and forex a headwind of 120bp.Q3 adjusted EBIT of € 474m (+10.0% y-o-y, margin of 10.0%) was 6% ahead of our estimate and 3% ahead of consensus expectations. Reported EB...
Underlying
FRESENIUS MEDICAL CARE AG

RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oliver Metzger

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch